Only THREE more days for families, patient advocacy groups, and researchers to give input into NIH’s new initiative on undiagnosed disease research. Do you have
CHAMP1 Research Foundation
The CHAMP1 Foundation is an organization created for parents of children with developmental delay, hypotonia, cerebral palsy, autism, and epilepsy among many other diagnoses a result of a change in the CHAMP1 gene.
Our vision is to find effective treatments and a cure for CHAMP1 disorders.
Our mission is to improve the lives of those affected by CHAMP1 disorders through clinical research, effective treatments, public awareness, early detection, family support and patient advocacy.
Our Goals: To coordinate and collaborate with the global scientific community to understand the function of the CHAMP1 gene in order to accelerate the develop of effective treatments and a cure for CHAMP1 disorders.
To increase the medical community and public awareness of the complexity and potential severity of CHAMP1 disorders.
To provide educational and emotional support for those affected by CHAMP1 disorders.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With the CHAMP1 Foundation
Patient Worthy Posts on CHAMP1 Disorders will be Coming Soon!
According to a story from BioPharma Dive, the drug company Sarepta Therapeutics is pushing forward with its plans to develop a gene therapy for limb-girdle
According to a story from BioPharma Dive, the advent of gene therapy development at Spark Therapeutics has been five years in the making. At this
A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
According to a story from Acrofan, the biotechnology company Clover Pharmaceuticals Inc. has recently announced that the first patient has been dosed in its phase
Elloise Charles has set out on a mission to raise awareness and money for progressive supranuclear palsy (PSP) after her father was diagnosed. His journey
Researchers at BGN Technologies (at Ben-Gurion University) have come up with a new way to predict and monitor progression of a wide array of neurodegenerative